Arbutus Biopharma (ABUS) Current Deferred Revenue (2016 - 2025)
Historic Current Deferred Revenue for Arbutus Biopharma (ABUS) over the last 13 years, with Q1 2025 value amounting to $6.8 million.
- Arbutus Biopharma's Current Deferred Revenue fell 4146.53% to $6.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $6.8 million, marking a year-over-year decrease of 4146.53%. This contributed to the annual value of $7.6 million for FY2024, which is 3579.0% down from last year.
- Per Arbutus Biopharma's latest filing, its Current Deferred Revenue stood at $6.8 million for Q1 2025, which was down 4146.53% from $7.6 million recorded in Q4 2024.
- Arbutus Biopharma's 5-year Current Deferred Revenue high stood at $23.3 million for Q1 2022, and its period low was $6.8 million during Q1 2025.
- Its 4-year average for Current Deferred Revenue is $13.4 million, with a median of $12.1 million in 2023.
- In the last 5 years, Arbutus Biopharma's Current Deferred Revenue tumbled by 969.78% in 2023 and then crashed by 4146.53% in 2025.
- Over the past 4 years, Arbutus Biopharma's Current Deferred Revenue (Quarter) stood at $16.5 million in 2022, then fell by 28.35% to $11.8 million in 2023, then crashed by 35.79% to $7.6 million in 2024, then dropped by 10.73% to $6.8 million in 2025.
- Its Current Deferred Revenue was $6.8 million in Q1 2025, compared to $7.6 million in Q4 2024 and $10.9 million in Q3 2024.